Norepinephrine

Norepinephrine is a medicine given into a vein. The US label for the brand LEVOPHED lists it to raise blood pressure in adults with severe, acute hypotension (very low blood pressure that starts suddenly). The label calls it a catecholamine and says it narrows blood vessels and stimulates the heart. The body also makes norepinephrine as a nerve-signal chemical.

Also called Norepinephrine bitartrate · Levophed

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 7512; UNII IFY5PE3ZRW is the UNII of the salt, norepinephrine bitartrate, that the label gives, so it is a broad match; MeSH descriptor D009638 (Norepinephrine). US drug-label class: Catecholamine (established pharmacologic class, RxClass). The label read is the Hospira label for LEVOPHED, application NDA007513, effective 2025-06-12 in openFDA; other makers and premixed products sold under other applications were not read. The label does not name shock in the indication sentences read. This page records the label indication and the class only: no trial result and no dose is given. The parent class page (inotropes and vasopressors) is not written yet, so the page has no parent link. No condition page for hypotension exists yet, so the page has no condition link.

Trials at a glance

The figures count the 1 registry trial in this atlas that names this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
1
Phase 3 or 4
1
Recruiting
1
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseRecruitingAll statuses
Phase 411
All phases11

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

About this drug

Level
Substance
Mechanism
The label describes norepinephrine as a peripheral vasoconstrictor (alpha-adrenergic action) and an inotropic stimulator of the heart (beta-adrenergic action).

Classification codes

  • UNII IFY5PE3ZRW Norepinephrine bitartrate

Claims and evidence

Context Adults for whom the US LEVOPHED label lists raising blood pressure: severe, acute hypotension or acute hypotensive states

Recipient
Adult
Population
Adult patients with severe, acute hypotension or acute hypotensive states, as the indications section describes them.
Care setting
Intravenous medicine (route in the openFDA record: intravenous)
Geography
United States (label of the US Food and Drug Administration)
Life stage
Adults, as the label states
Follow-up
Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
Included
  • Adult patients with severe, acute hypotension
  • Adult patients with acute hypotensive states
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of LEVOPHED (norepinephrine bitartrate, Hospira, NDA007513; version dated 12 June 2025 in openFDA) lists it to raise blood pressure in adult patients with severe, acute hypotension. The label calls it a catecholamine for restoring blood pressure in adults with acute hypotensive states.

    Applies to Adult Adults for whom the US LEVOPHED label lists raising blood pressure: severe, acute hypotension or acute hypotensive states

    Certainty method
    Not assessed
    Limitations
    This claim records what one label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded. The label does not name cardiogenic shock or septic shock in the sentences read. Only the indications section and the mechanism sentence were read; warnings, doses and adverse reactions were not recorded. Other makers and a premixed product are sold under other applications, which were not read. openFDA says its data are unvalidated and not to be relied on for decisions about medical care.
    Last checked
    2026-11-08
    Next evidence check due
    Not scheduled
    Sources and citations (5)
    1. Supports openFDA drug label record: LEVOPHED norepinephrine bitartrate (Hospira, NDA007513)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record, label effective 20250612, dataset last updated 2026-11-06. · SPL set id: c4de72a8-2a75-4984-ce90-e4870226dc12

      Locator
      results[0].openfda.application_number[0]
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2025-06-12
      Source state
      Current
      Version fingerprint
      50eef227839336a5ca244131ecd96bd330e7874d989cff9fec2a7903d7b9cfa6
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Supports openFDA drug label record: LEVOPHED norepinephrine bitartrate (Hospira, NDA007513)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record, label effective 20250612, dataset last updated 2026-11-06. · SPL set id: c4de72a8-2a75-4984-ce90-e4870226dc12

      Locator
      results[0].effective_time
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2025-06-12
      Source state
      Current
      Version fingerprint
      50eef227839336a5ca244131ecd96bd330e7874d989cff9fec2a7903d7b9cfa6
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports openFDA drug label record: LEVOPHED norepinephrine bitartrate (Hospira, NDA007513)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record, label effective 20250612, dataset last updated 2026-11-06. · SPL set id: c4de72a8-2a75-4984-ce90-e4870226dc12

      Locator
      results[0].openfda.brand_name[0]
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2025-06-12
      Source state
      Current
      Version fingerprint
      50eef227839336a5ca244131ecd96bd330e7874d989cff9fec2a7903d7b9cfa6
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
    4. Supports openFDA drug label record: LEVOPHED norepinephrine bitartrate (Hospira, NDA007513)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record, label effective 20250612, dataset last updated 2026-11-06. · SPL set id: c4de72a8-2a75-4984-ce90-e4870226dc12

      Locator
      results[0].indications_and_usage[0], 1 sentence 1
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2025-06-12
      Source state
      Current
      Version fingerprint
      50eef227839336a5ca244131ecd96bd330e7874d989cff9fec2a7903d7b9cfa6
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
    5. Supports openFDA drug label record: LEVOPHED norepinephrine bitartrate (Hospira, NDA007513)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record, label effective 20250612, dataset last updated 2026-11-06. · SPL set id: c4de72a8-2a75-4984-ce90-e4870226dc12

      Locator
      results[0].indications_and_usage[0], 1 sentence 2
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2025-06-12
      Source state
      Current
      Version fingerprint
      50eef227839336a5ca244131ecd96bd330e7874d989cff9fec2a7903d7b9cfa6
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

LEVOPHED

No label from the application holder was found in the openFDA label dataset for application NDA007513. This page does not show another labeler's label in its place.

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

No label from the application holder was found in the openFDA label dataset for application NDA214628. This page does not show another labeler's label in its place.

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

No label from the application holder was found in the openFDA label dataset for application NDA215700. This page does not show another labeler's label in its place.

NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

No label from the application holder was found in the openFDA label dataset for application NDA214313. This page does not show another labeler's label in its place.

RAVOCAINE AND NOVOCAIN W/ LEVOPHED

No label from the application holder was found in the openFDA label dataset for application NDA008592. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA007513 LEVOPHED
  2. Approval NDA008592 RAVOCAINE AND NOVOCAIN W/ LEVOPHED
  3. Approval NDA214313 NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE
  4. Approval NDA215700 NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
  5. Approval NDA214628 NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 5

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA007513

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record. FDA lists it under 2 brand...

    ProductNDA008592

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record. FDA lists it under 2 brand...

    ProductNDA214313

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA214628

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA215700

Registry trials 1

Record details

Record id
cardio:norepinephrine
Content hash
74725163653b687216927c6f6e8e430166f94bf4ba7fc12852f06d071170c75c